New Delhi, April 4 – India’s drug regulators are increasing their oversight of rapidly growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.This move comes as the...